









市場行情
/
股票
/
nasdaq-tgtx
/

TG Therapeutics Inc

TGTX

31.070USD

+0.340+1.11%

收盤 12/24, 16:00（美東）報價延遲15分鐘

4.82B總市值

10.15本益比TTM



TG Therapeutics Inc

31.070

+0.340+1.11%

概覽公司財務分析

概覽

公司

財務

分析

關於 TG Therapeutics Inc 公司

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

TG Therapeutics Inc簡介



公司代碼TGTX

公司名稱TG Therapeutics Inc

上市日期Dec 14, 1995

CEOWeiss (Michael S)

員工數量338

證券類型Ordinary Share

年結日Dec 14

公司地址3020 Carrington Mill Blvd., Suite 475

城市MORRISVILLE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編27560-5435

電話18775758489

網址https://www.tgtherapeutics.com/

公司代碼TGTX

上市日期Dec 14, 1995

CEOWeiss (Michael S)

TG Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Michael S. Weiss, J.D.

Chairman of the Board, President, Chief Executive Officer

9.16M

-33.77%

Mr. Sean A. Power

Chief Financial Officer, Treasurer, Corporate Secretary

600.61K

-19.72%

Mr. Kenneth (Ken) Hoberman

Independent Director

279.65K

+5.56%

Dr. Yann Echelard

Independent Director

223.82K

-2.19%

Mr. Laurence Neil (Larry) Charney, CPA

Lead Independent Director

222.89K

+10.63%

Mr. Daniel Hume, J.D.

Independent Director

192.75K

+8.27%

Dr. Sagar Lonial

Independent Director

94.06K

-18.15%

名稱

名稱/職務

職務

持股

持股變動

Mr. Michael S. Weiss, J.D.

Chairman of the Board, President, Chief Executive Officer

9.16M

-33.77%

Mr. Sean A. Power

Chief Financial Officer, Treasurer, Corporate Secretary

600.61K

-19.72%

Mr. Kenneth (Ken) Hoberman

Independent Director

279.65K

+5.56%

Dr. Yann Echelard

Independent Director

223.82K

-2.19%

Mr. Laurence Neil (Larry) Charney, CPA

Lead Independent Director

222.89K

+10.63%

Mr. Daniel Hume, J.D.

Independent Director

192.75K

+8.27%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q1

FY2024

業務USD

名稱

營收

佔比

Total product revenue, net

119.66M

99.01%

Royalty Revenue

605.00K

0.50%

Other Revenue

558.00K

0.46%

License Revenue

38.00K

0.03%

Milestone Revenue

0.00

0.00%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Total product revenue, net

119.66M

99.01%

Royalty Revenue

605.00K

0.50%

Other Revenue

558.00K

0.46%

License Revenue

38.00K

0.03%

Milestone Revenue

0.00

0.00%

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

11.86%

The Vanguard Group, Inc.

9.75%

Weiss (Michael S)

5.77%

State Street Investment Management (US)

5.10%

ClearBridge Investments, LLC

2.93%

其他

64.59%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

11.86%

The Vanguard Group, Inc.

9.75%

Weiss (Michael S)

5.77%

State Street Investment Management (US)

5.10%

ClearBridge Investments, LLC

2.93%

其他

64.59%

股東類型

持股股東

佔比

Investment Advisor

34.37%

Investment Advisor/Hedge Fund

17.35%

Hedge Fund

7.07%

Individual Investor

6.78%

Research Firm

3.06%

Pension Fund

1.30%

Bank and Trust

0.39%

Family Office

0.13%

Sovereign Wealth Fund

0.06%

其他

29.49%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

698

101.46M

63.91%

-17.24M

2025Q2

693

115.94M

73.03%

-21.56M

2025Q1

704

116.82M

73.80%

-25.76M

2024Q4

657

113.87M

72.65%

-36.14M

2024Q3

598

117.83M

76.11%

-20.28M

2024Q2

544

109.58M

70.90%

-28.91M

2024Q1

535

105.41M

68.45%

-29.01M

2023Q4

542

104.64M

69.13%

-36.73M

2023Q3

552

104.67M

69.33%

-30.54M

2023Q2

543

102.45M

68.58%

-35.33M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

19.13M

12.06%

-84.56K

-0.44%

Jun 30, 2025

The Vanguard Group, Inc.

15.77M

9.94%

+203.00K

+1.30%

Jun 30, 2025

Weiss (Michael S)

13.82M

8.71%

Apr 14, 2025

State Street Investment Management (US)

7.62M

4.8%

+184.34K

+2.48%

Jun 30, 2025

ClearBridge Investments, LLC

3.05M

1.92%

+408.10K

+15.43%

Jun 30, 2025

Soleus Capital Management, L.P.

2.24M

1.41%

-602.77K

-21.17%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.49M

2.2%

+207.89K

+6.33%

Jun 30, 2025

Pictet Asset Management Ltd.

1.91M

1.2%

-489.69K

-20.43%

Jun 30, 2025

Hood River Capital Management LLC

1.57M

0.99%

+11.02K

+0.71%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco S&P SmallCap Health Care ETF

2.89%

State Street SPDR S&P Biotech ETF

1.93%

Virtus LifeSci Biotech Products ETF

1.49%

Invesco S&P SmallCap 600 Pure Growth ETF

1.44%

Invesco S&P SmallCap Momentum ETF

1.4%

Direxion Daily S&P Biotech Bull 3X Shares

1.11%

State Street SPDR S&P 600 Small Cap Growth ETF

0.65%

First Trust NASDAQ Pharmaceuticals ETF

0.63%

Principal U.S. Small-Cap ETF

0.62%

Vanguard S&P Small-Cap 600 Growth Index Fund

0.61%

Invesco S&P SmallCap Health Care ETF

佔比2.89%

State Street SPDR S&P Biotech ETF

佔比1.93%

Virtus LifeSci Biotech Products ETF

佔比1.49%

Invesco S&P SmallCap 600 Pure Growth ETF

佔比1.44%

Invesco S&P SmallCap Momentum ETF

佔比1.4%

Direxion Daily S&P Biotech Bull 3X Shares

佔比1.11%

State Street SPDR S&P 600 Small Cap Growth ETF

佔比0.65%

First Trust NASDAQ Pharmaceuticals ETF

佔比0.63%

Principal U.S. Small-Cap ETF

佔比0.62%

Vanguard S&P Small-Cap 600 Growth Index Fund

佔比0.61%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

TG Therapeutics Inc的前五大股東是誰？



TG Therapeutics Inc的前五大股東如下：
BlackRock Institutional Trust Company, N.A.
持有股份：19.13M
佔總股份比例：12.06%。
The Vanguard Group, Inc.
持有股份：15.77M
佔總股份比例：9.94%。
Weiss (Michael S)
持有股份：13.82M
佔總股份比例：8.71%。
State Street Investment Management (US)
持有股份：7.62M
佔總股份比例：4.80%。
ClearBridge Investments, LLC
持有股份：3.05M
佔總股份比例：1.92%。